This “Pediatric Growth Hormone Deficiency - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Pediatric Growth Hormone Deficiency pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Pediatric Growth Hormone Deficiency - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pediatric Growth Hormone Deficiency pipeline landscape is provided which includes the disease overview and Pediatric Growth Hormone Deficiency treatment guidelines. The assessment part of the report embraces, in depth Pediatric Growth Hormone Deficiency commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pediatric Growth Hormone Deficiency collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Somatrogon: OPKO Health Somatrogon is a recombinant protein comprising of human growth hormone (hGh). It is a novel molecule with receptor binding properties and mechanism of action similar to hGh. The drug is in phase III and is developed for the treatment of growth hormonedeficiency.
This product will be delivered within 2 business days.
Geography Covered
- Global coverage
Pediatric Growth Hormone Deficiency Understanding
Pediatric Growth Hormone Deficiency: Overview
Growth hormone deficiency (GHD) is caused when the pituitary gland or the hypothalamus is not functioning properly and does not produce enough growth hormone. GHD can be acquired or congenital. Children with GHD have abnormally short stature with normal body proportions. GHD affects male and female equally. Symptoms include slow growth, delayed sexual development, and others.Pediatric Growth Hormone Deficiency - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pediatric Growth Hormone Deficiency pipeline landscape is provided which includes the disease overview and Pediatric Growth Hormone Deficiency treatment guidelines. The assessment part of the report embraces, in depth Pediatric Growth Hormone Deficiency commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pediatric Growth Hormone Deficiency collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Pediatric Growth Hormone Deficiency R&D. The therapies under development are focused on novel approaches to treat/improve Pediatric Growth Hormone Deficiency.Pediatric Growth Hormone Deficiency Emerging Drugs Chapters
This segment of the Pediatric Growth Hormone Deficiency report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.Pediatric Growth Hormone Deficiency Emerging Drugs
Lonapegsomatropin: Ascendis Pharma A/SLonapegsomatropin is a growth hormone. It is currently being developed for the treatment of growth hormone deficiency. The drug molecule works as a somatotropin receptor agonist. It is currently in pre-registration phase.Somatrogon: OPKO Health Somatrogon is a recombinant protein comprising of human growth hormone (hGh). It is a novel molecule with receptor binding properties and mechanism of action similar to hGh. The drug is in phase III and is developed for the treatment of growth hormonedeficiency.
Pediatric Growth Hormone Deficiency: Therapeutic Assessment
This segment of the report provides insights about the different Pediatric Growth Hormone Deficiency drugs segregated based on following parameters that define the scope of the report, such as:Major Players in Pediatric Growth Hormone Deficiency
There are approx. 5+ key companies which are developing the therapies for Pediatric Growth Hormone Deficiency. The companies which have their Pediatric Growth Hormone Deficiency drug candidates in the most advanced stage, i.e. phase Pre-registration include, Ascendis Pharma A/S.Phases
This report covers around 5+ products under different phases of clinical development like- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Pediatric Growth Hormone Deficiency pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.Pediatric Growth Hormone Deficiency: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pediatric Growth Hormone Deficiency therapeutic drugs key players involved in developing key drugs.Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pediatric Growth Hormone Deficiency drugs.Pediatric Growth Hormone Deficiency Report Insights
- Pediatric Growth Hormone Deficiency Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Pediatric Growth Hormone Deficiency Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:- How many companies are developing Pediatric Growth Hormone Deficiency drugs?
- How many Pediatric Growth Hormone Deficiency drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pediatric Growth Hormone Deficiency?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pediatric Growth Hormone Deficiency therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Pediatric Growth Hormone Deficiency and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Ascendis Pharma
- OPKO Health
- Aravive
Key Products
- Lonapegsomatropin
- Somatrogon
- VRS-317
This product will be delivered within 2 business days.
Table of Contents
IntroductionExecutive SummaryPediatric Growth Hormone Deficiency - Analytical PerspectiveDrug profiles in the detailed report…..Pediatric Growth Hormone Deficiency Key CompaniesPediatric Growth Hormone Deficiency Key ProductsPediatric Growth Hormone Deficiency- Unmet NeedsPediatric Growth Hormone Deficiency- Market Drivers and BarriersPediatric Growth Hormone Deficiency- Future Perspectives and ConclusionPediatric Growth Hormone Deficiency Analyst ViewsPediatric Growth Hormone Deficiency Key CompaniesAppendix
Pediatric Growth Hormone Deficiency: Overview
Pipeline Therapeutics
Therapeutic Assessment
In-depth Commercial Assessment
Pediatric Growth Hormone Deficiency Collaboration Deals
Late Stage Products (Phase Pre-registration)
Lonapegsomatropin: Ascendis Pharma
Late Stage Products (Phase III)
Somatrogon: OPKO Health
Inactive Products
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Ascendis Pharma
- OPKO Health
- Aravive